Categories Earnings, Health Care

Bristol-Myers Squibb (BMY) slips to a loss in Q4 but beats estimates

Bristol-Myers Squibb Company (NYSE: BMY) slipped to a loss in the fourth quarter of 2019 from a profit last year, due to the amortization of acquired intangible assets related to the Celgene purchase. However, the results exceeded analysts’ expectations. Further, the company issued earnings and revenue guidance for the full year 2020 that came in line with the consensus view.

Net loss was $1.06 billion or $0.55 per share compared to a profit of $1.16 billion or $0.71 per share in the previous year quarter. Adjusted earnings increased by 30% to $1.22 per share.

Bristol-Myers Squibb (BMY) Q4 2019 earnings results

Revenue jumped by 33% to $7.95 billion. Analysts had expected EPS of $0.88 per share on revenue of $6.14 billion for the fourth quarter. The top-line was driven by the Celgene acquisition, which was closed on November 20, 2019. Revenue climbed by 34% when adjusted for foreign exchange impact.

Looking ahead into fiscal 2020, the company expects unadjusted earnings in the range of $0.75-0.95 per share and adjusted earnings in the range of $6.00-6.20 per share. Revenue is predicted to be $40.5-42.5 billion for the full year. The consensus estimates EPS of $6.16 on revenue of $42.2 billion for the full year 2020.

Product-wise, sales of anticoagulant Eliquis and Sprycel moved up 19% and 2% respectively, year-over-year, while sales of melanoma drug Yervoy remained flat. The sales of anti-cancer drug Opdivo declined by 2% while anticoagulant drug Eliquis jumped by 19%.

Read: Humana Q4 earnings snapshot

The US revenues increased 42% to $4.8 billion in the quarter. International revenues increased 21% to $3.2 billion. When adjusted for foreign exchange impact, international revenues increased by 23%.

On Wednesday, Bristol-Myers Squibb issued a statement related to the global health emergency concerning the spread of the 2019 Novel Coronavirus. The company, which has limited and restricted employee travel to and from China, does not expect any disruptions to the supply of medicines for patients.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Comments

  1. Pingback: Seattle University
  2. Pingback: MBA in FUE
  3. Pingback: Credit Hour System
  4. Pingback: Grading Policy
  5. Pingback: taijutsu
  6. Pingback: cage a squat
  7. Pingback: liv pure
  8. Pingback: Fiverr Earn
  9. Pingback: fiverrearn.com
  10. Pingback: fiverrearn.com
  11. Pingback: fiverrearn.com
  12. Pingback: flatbed broker
  13. Pingback: clima
  14. Pingback: french bulldog
  15. Pingback: fiverrearn.com
  16. Pingback: fiverrearn.com
  17. Pingback: micro bully
  18. Pingback: crypto news
  19. Pingback: clima hoy new york
  20. Pingback: best Samsung
  21. Pingback: smartphones
  22. Pingback: best mobile phone
  23. Pingback: future university
  24. Pingback: future university
  25. Pingback: multisbo
  26. Pingback: FiverrEarn
  27. Pingback: fue
  28. Pingback: lean six sigma
  29. Pingback: Piano relocation
  30. Pingback: FUE
  31. Pingback: MB Removals
  32. Pingback: Classic Books 500
  33. Pingback: Media
  34. Pingback: Streamer
  35. Pingback: FiverrEarn
  36. Pingback: Becoming Porn star
  37. Pingback: partners
  38. Pingback: puradrop gummies
  39. Pingback: frenchie puppies
  40. Pingback: FiverrEarn
  41. Pingback: FiverrEarn
  42. Pingback: FiverrEarn
  43. Pingback: FiverrEarn
  44. Pingback: FiverrEarn
  45. Pingback: FiverrEarn
  46. Pingback: FiverrEarn
  47. Pingback: FiverrEarn
  48. Pingback: FiverrEarn
  49. Pingback: Supper
  50. Pingback: web design
  51. Pingback: Kuliah Termurah
  52. Pingback: FiverrEarn
  53. Pingback: FiverrEarn
  54. Pingback: FiverrEarn
  55. Pingback: cheap sex cams
  56. Pingback: live sex cams
  57. Pingback: frt trigger
  58. Pingback: abogado fiscal
  59. Pingback: 늑대닷컴
  60. Pingback: Bonus buy slot
  61. Pingback: nangs near me
  62. Pingback: allgame
  63. Pingback: 918kiss
  64. Pingback: หวย24
  65. Pingback: Skincare
  66. Pingback: pg slot
  67. Pingback: 6.5 prc ammo
  68. Pingback: ItMe.Xyz
  69. Pingback: MasumINTL.Com
  70. Pingback: ItMe.Xyz
  71. Pingback: ItMe.Xyz
  72. Pingback: ItMe.Xyz
  73. Pingback: itme.xyz

Comments are closed.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top